_Admin Core The Administrative Core will provide management services to each of the Projects and Cores in this Program, as well as financial, administrative, and clerical services for the PI, Project Leaders, and Core Leaders for all grant-related activities. These activities include preparation of this competing renewal, non-competing renewals including progress reports, preparation of budgets, communication with the NIH regarding renewals and all financial interactions, and assurance that the labs supported by this Program are in full compliance with all institutional, state and federal regulations. The Administrative Core will also coordinate and schedule all meetings related to the function of the Program, including monthly meetings of all Project and Core leaders, and members of their respective laboratories, as well as annual meetings of the Internal and External Advisory Boards. Dr. Ebert is the PI and Director of this Core and will serve as the overall scientific director and chief administrator. Dr. Griffin is the is the co-Investigator of this Program and will assist in these operations, particularly regarding clinical programs and core facilities at the DFCI. He will also assist Dr. Ebert in monitoring protocol performance and will assist in protocol development. If Dr. Ebert is unable to continue his duties as PI, Dr. Griffin would assume that responsibility. Ms. Logan, highly skilled in management of fiscal and administrative matters for large program project grants, will serve as Administrative Facilitator, managing budgets between participating institutions, preparing reports including non-competing renewals, interfacing with the financial officers of each participating institution in the Program, and serving as an interface between these groups and the NIH. Dr. Levin will work with Ms. Logan to assure compliance and appropriate regulations regarding experimentation with human subjects (including gender and minority participation), and vertebrate animals, as well as compliance of publications, IRBs and IACUCs for all the projects. Ms. Logan and Dr. Levin will work closely with Dr. Ebert on the preparation of all necessary documents related to the activities in this Program Project grant.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA066996-21
Application #
9854838
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2025-04-30
Budget Start
2020-03-15
Budget End
2021-02-28
Support Year
21
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Nauffal, Mary; Redd, Robert; Ni, Jian et al. (2018) Single 6-mg dose of rasburicase: The experience in a large academic medical center. J Oncol Pharm Pract :1078155218791333
Stein, Eytan M; Garcia-Manero, Guillermo; Rizzieri, David A et al. (2018) The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 131:2661-2669
Hemming, Matthew L; Lawlor, Matthew A; Zeid, Rhamy et al. (2018) Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A 115:E5746-E5755
Kardosova, Miroslava; Zjablovskaja, Polina; Danek, Petr et al. (2018) C/EBP? is dispensable for steady-state and emergency granulopoiesis. Haematologica 103:e331-e335
Numata, Akihiko; Kwok, Hui Si; Kawasaki, Akira et al. (2018) The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia. Nat Commun 9:1622
Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497
Manley, Paul W; Weisberg, Ellen; Sattler, Martin et al. (2018) Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series ""Biochemistry to Bedside"". Biochemistry 57:477-478
Ebert, Benjamin L; Libby, Peter (2018) Clonal Hematopoiesis Confers Predisposition to Both Cardiovascular Disease and Cancer: A Newly Recognized Link Between Two Major Killers. Ann Intern Med 169:116-117
DiNardo, Courtney D; Pratz, Keith W; Letai, Anthony et al. (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19:216-228
Brien, Gerard L; Remillard, David; Shi, Junwei et al. (2018) Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife 7:

Showing the most recent 10 out of 376 publications